Targeted Sequencing in Chromosome 17q Linkage Region Identifies Familial Glioma Candidates in the Gliogene Consortium

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Jalali, Ali ^a   Amirian, E Susan ^a   Bainbridge, Matthew N ^a,b   Armstrong, Georgina N ^a   Liu, Yanhong ^a   Tsavachidis, Spyros ^a   Jhangiani, Shalini N ^a   Plon, Sharon E ^a   Lau, Ching C ^a   Claus, Elizabeth B ^c,d   Barnholtz Sloan, Jill S ^e   Il'yasova, Dora ^f,g   Schildkraut, Joellen ^g   Ali Osman, Francis ^g   Sadetzki, Siegal ^h,i   Johansen, Christoffer ^j,k   Houlston, Richard S ^l   Jenkins, Robert B ^m   Lachance, Daniel ^m   Olson, Sara H ⁿ   Bernstein, Jonine L ⁿ   Merrell, Ryan T ^o   Wrensch, Margaret R ^p   Davis, Faith G ^q   Lai, Rose ^r   Shete, Sanjay ^s   Aldape, Kenneth ^s   Amos, Christopher I ^t   Muzny, Donna M ^a   Gibbs, Richard A ^a   Melin, Beatrice S ^u   Bondy, Melissa L ^a   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Codified Genomics LLC ^*  (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GEORGIA STATE UNIVERSITY   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

ⁱ TEL AVIV UNIVERSITY   (Israel)

^j INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

^l INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^m MAYO CLINIC CANCER CENTER   (United States)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q UNIVERSITY OF ALBERTA   (Canada)

^r UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^s UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^t DARTMOUTH MEDICAL SCHOOL   (United States)

^u UMEÅ UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BRAIN TUMOR; CHROMOSOME 17; DNA SEQUENCE; FAMILY; FEMALE; GENETIC LINKAGE; GENETIC VARIABILITY; GENETICS; GLIOMA; HUMAN; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PEDIGREE; YOUNG ADULT;

ADULT; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FAMILY; FEMALE; GENETIC LINKAGE; GENETIC VARIATION; GLIOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; PEDIGREE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84954416682     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08278     Document Type: Article

References (57)

1. Adamson, C. et al. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 18, 1061-83 (2009).
2. Ohgaki, H. & Kleihues, P. Epidemiology and etiology of gliomas. Acta Neuropathol 109, 93-108 (2005).
3. Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D. & Wrensch, M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2, 494-503; quiz 1 p following 516 (2006).
4. Ostrom, Q. T. et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15 Suppl 2, ii1-56 (2013).
5. Ostrom, Q. T. et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol 16, 896-913 (2014).
6. Liu, Y. et al. Genetic advances in glioma: susceptibility genes and networks. Curr Opin Genet Dev 20, 239-44 (2010).
7. Melin, B. & Jenkins, R. Genetics in glioma: lessons learned from genome-wide association studies. Curr Opin Neurol 26, 688-92 (2013).
8. Rajaraman, P. et al. Genome-wide association study of glioma and meta-analysis. Hum Genet 131, 1877-88 (2012).
9. Melin, B. et al. Known glioma risk loci are associated with glioma with a family history of brain tumours - a case-control gene association study. Int J Cancer 132, 2464-8 (2013).
10. Shete, S. et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41, 899-904 (2009).
11. Sadetzki, S. et al. Description of selected characteristics of familial glioma patients - results from the Gliogene Consortium. Eur J Cancer 49, 1335-45 (2013).
12. Scheurer, M. E. et al. Familial aggregation of glioma: a pooled analysis. Am J Epidemiol 172, 1099-107 (2010).
13. Shete, S. et al. Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium. Cancer Res 71, 7568-75 (2011).
14. Malmer, B. et al. GLIOGENE an International Consortium to Understand Familial Glioma. Cancer Epidemiol Biomarkers Prev 16, 1730-4 (2007).
15. Sun, X. et al. A variable age of onset segregation model for linkage analysis, with correction for ascertainment, applied to glioma. Cancer Epidemiol Biomarkers Prev 21, 2242-51 (2012).
16. Adikes, R. C., Unrath, W. C., Yengo, C. M. & Quintero, O. A. Biochemical and bioinformatic analysis of the myosin-XIX motor domain. Cytoskeleton (Hoboken) 70, 281-95 (2013).
17. Edgren, H. et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol 12, R6 (2011).
18. Stout, J. R. et al. Kif18B interacts with EB1 and controls astral microtubule length during mitosis. Mol Biol Cell 22, 3070-80 (2011).
19. Lee, Y. M. et al. Cell cycle-regulated expression and subcellular localization of a kinesin-8 member human KIF18B. Gene 466, 16-25 (2010).
20. Rath, O. & Kozielski, F. Kinesins and cancer. Nat Rev Cancer 12, 527-39 (2012).
21. Itzel, T. S. P., Maass, T., Krupp, M., Marquardt, J. U., Strand, S., Becker, D., Staib, F., Binder, H., Wang, X. W., Thorgeirsson, S. S., Galle, P. R. & Teufel, A. Translating bioinformatics in oncology: Guilty by profiling meta-analysis and identification of KIF18B and CDCA3 as novel driver genes in liver carcinogenesis. Z Gastroenterol 51, 4-26 (2013).
22. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46, 310-5 (2014).
23. Suri, A. et al. Cancer testis antigens: A new paradigm for cancer therapy. Oncoimmunology 1, 1194-1196 (2012).
24. Yi, F. et al. SPAG9 is overexpressed in human astrocytoma and promotes cell proliferation and invasion. Tumour Biol 34, 2849-55 (2013).
25. Takaesu, G. et al. Activation of p38alpha/beta MAPKin myogenesis via binding of the scaffold protein JLP to the cell surface protein Cdo. J Cell Biol 175, 383-8 (2006).
26. Sinha, A. et al. Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy. J Exp Clin Cancer Res 32, 69 (2013).
27. Garg, M. et al. Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer 115, 2671-83 (2009).
28. Kanojia, D. et al. Sperm associated antigen 9 plays an important role in bladder transitional cell carcinoma. PLoS One 8, e81348 (2013).
29. Seleit, I., Bakry, O. A., Samaka, R. M. & Malak, M. A. Immunohistochemical Expression of Sperm-Associated Antigen 9 in Nonmelanoma Skin Cancer. Am J Dermatopathol (2014) In press. DOI: 10.1097/DAD.0000000000000126.
30. Garg, M. et al. Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer. J Clin Endocrinol Metab 94, 4613-8 (2009).
31. Wang, Y. et al. Clinical significance and biological roles of SPAG9 overexpression in non-small cell lung cancer. Lung Cancer 81, 266-72 (2013).
32. Xie, C., Fu, L., Liu, N. & Li, Q. Overexpression of SPAG9 correlates with poor prognosis and tumor progression in hepatocellular carcinoma. Tumour Biol 35, 7685-91 (2014).
33. Li, H. et al. SPAG9 is overexpressed in human prostate cancer and promotes cancer cell proliferation. Tumour Biol 35, 6949-54 (2014).
34. Baser, E. et al. Sperm-associated antigen 9 is a promising marker for early diagnosis of endometrial cancer. Asian Pac J Cancer Prev 14, 7635-8 (2013).
35. Forsyth, P.A. et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79, 1828-35 (1999).
36. Apodaca, G. et al. Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 50, 2322-9 (1990).
37. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc 4, 1073-81 (2009).
38. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat Methods 7, 248-9 (2010).
39. Llanos, S., Efeyan, A., Monsech, J., Dominguez, O. & Serrano, M. A highthroughput loss-of-function screening identifies novel p53 regulators. Cell Cycle 5, 1880-5 (2006).
40. Song, Q. et al. Gene expression analysis on a photodiode array-based bioluminescence analyzer by using sensitivity-improved SRPP. Analyst 135, 1315-9 (2010).
41. Mutel, E. et al. Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas. J Hepatol 54, 529-37 (2011).
42. Lal, A. et al. A public database for gene expression in human cancers. Cancer Res 59, 5403-7 (1999).
43. Egland, K. A. et al. High expression of a cytokeratin-associated protein in many cancers. Proc Natl Acad Sci U S A 103, 5929-34 (2006).
44. Hu, L., Crowe, D. L., Rheinwald, J. G., Chambon, P. & Gudas, L. J. Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Cancer Res 51, 3972-81 (1991).
45. Shao, M. M. et al. Keratin expression in breast cancers. Virchows Arch 461, 313-22 (2012).
46. Paunu, N. et al. A novel low-penetrance locus for familial glioma at 15q23-q26.3. Cancer Res 62, 3798-802 (2002).
47. Robertson, L. B. et al. Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation. Fam Cancer 9, 413-21 (2010).
48. Reid, J. G. et al. Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis pipeline. BMC Bioinformatics 15, 30 (2014).
49. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-60 (2009).
50. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-9 (2009).
51. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43, 491-8 (2011).
52. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38, e164 (2010).
53. Futreal, P. A. et al. A census of human cancer genes. Nat Rev Cancer 4, 177-83 (2004).
54. Fu, W. et al. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature 493, 216-20 (2013).
55. Genomes Project, C. et al An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
56. Davydov, E. V. et al. Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Comput Biol 6, e1001025 (2010).
57. Cooper, G. M. et al. Distribution and intensity of constraint in mammalian genomic sequence. Genome Res 15, 901-13 (2005).